Patients With Aggressive Brain and Advanced Liver Cancers Treated with Geneos’ Personalized Immunotherapy for Cancer as Monotherapy Reach Five Years of Durable Recurrence-Free Survival
Geneos Therapeutics, a clinical-stage biotherapeutics company developing personalized immunotherapies for cancer (PICs), today announced that two patients with aggressive cancers – one with glioblastoma multiforme (GBM), and another with advanced hepatocellular carcinoma (HCC) treated in the second line – remain on personalized immunotherapy for cancer (PIC) monotherapy, recurrence free and healthy, after more than six years and five years of ongoing treatment, respectively. Both achieved complete responses and neither has experienced any PIC-related adverse event greater than Grade 1 nor any PIC-related serious adverse event. Additional clinical trial patients with GBM and advanced HCC receiving PIC monotherapy continue to progress toward five years of recurrence-free survival.
